Literature DB >> 17094777

Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.

Maarten Naesens1, Kristin Verbeke, Yves Vanrenterghem, Dirk Kuypers.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Strategies that are more elaborate than measuring predose plasma concentrations are required for the therapeutic monitoring of mycophenolic acid (MPA). * Previous studies in healthy subjects and diabetes patients have suggested that MPA pharmacokinetics are influenced by gastric emptying, but this has not been demonstrated directly. WHAT THIS STUDY ADDS: * This study has investigated the relationship between gastric emptying, measured directly (using the (14)C octanoate and (13)C glycine breath tests) and the steady-state plasma concentration-time profile of MPA. * Delayed gastric emptying was associated with a longer t(max) and lower C(max), but total exposure to MPA was not affected. * The findings suggest that it could be misleading to rely fully on short-term (<2 h) limited sampling strategies for MPA therapeutic monitoring in recipients with gastric emptying disorders, the latter occurring relatively frequently in solid organ transplantation. AIM: To investigate the effect of gastric emptying on the pharmacokinetics of mycophenolic acid (MPA) in renal transplant patients.
METHODS: We assessed the effect of gastric emptying on the disposition of MPA in 27 stable renal allograft recipients at 2 years after transplantation. Gastric emptying was measured by the (14)C-octanoate and (13)C-glycine breath test.
RESULTS: Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075]. Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].
CONCLUSION: Delayed gastric emptying was associated with a slower absorption of MPA, a longer time to reach peak concentrations and lower maximum concentrations. These effects should be taken into account when validating limited (<2 h) sampling strategies to estimate total MPA exposure, which could be unreliable when monitoring patients with gastric emptying disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094777      PMCID: PMC2000747          DOI: 10.1111/j.1365-2125.2006.02813.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

Review 1.  Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies.

Authors:  Leslie M Shaw; Magdalena Korecka; Raman Venkataramanan; Lee Goldberg; Roy Bloom; Kenneth L Brayman
Journal:  Am J Transplant       Date:  2003-05       Impact factor: 8.086

2.  Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration.

Authors:  R Bullingham; S Monroe; A Nicholls; M Hale
Journal:  J Clin Pharmacol       Date:  1996-04       Impact factor: 3.126

Review 3.  Mycophenolate mofetil and its mechanisms of action.

Authors:  A C Allison; E M Eugui
Journal:  Immunopharmacology       Date:  2000-05

Review 4.  Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.

Authors:  J M Greiff; D Rowbotham
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

5.  Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs.

Authors:  D A Armbruster; M D Tillman; L M Hubbs
Journal:  Clin Chem       Date:  1994-07       Impact factor: 8.327

6.  Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.

Authors:  M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq
Journal:  Clin Chem       Date:  2001       Impact factor: 8.327

7.  Impairment of mycophenolate mofetil absorption by iron ion.

Authors:  M Morii; K Ueno; A Ogawa; R Kato; H Yoshimura; K Wada; H Hashimoto; M Takada; K Tanaka; T Nakatani; M Shibakawa
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

8.  The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.

Authors:  Lutz T Weber; Maria Shipkova; Victor W Armstrong; Natalie Wagner; Ekkehard Schütz; Otto Mehls; Lothar B Zimmerhackl; Michael Oellerich; Burkhard Tönshoff
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

9.  Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids.

Authors:  B D Maes; Y F Ghoos; B J Geypens; G Mys; M I Hiele; P J Rutgeerts; G Vantrappen
Journal:  J Nucl Med       Date:  1994-05       Impact factor: 10.057

10.  Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.

Authors:  D R Kuypers; K Claes; P Evenepoel; B Maes; W Coosemans; J Pirenne; Y Vanrenterghem
Journal:  J Clin Pharmacol       Date:  2003-08       Impact factor: 3.126

View more
  5 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Drug therapy in kidney disease.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

3.  Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds.

Authors:  M Grobman; D M Boothe; H Rindt; B G Williamson; M L Katz; J R Coates; C R Reinero
Journal:  J Vet Pharmacol Ther       Date:  2017-06-25       Impact factor: 1.786

4.  Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.

Authors:  Jeong M Park; Kathleen D Lake; Diane M Cibrik
Journal:  Ther Drug Monit       Date:  2008-10       Impact factor: 3.681

5.  Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients.

Authors:  Chirag G Patel; Katherine Richman; Dongfang Yang; Bingfang Yan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.